Biotechnology News and Research

RSS

NEOMED gets $12 million to support academic researchers on drug development

NEOMED, a not-for-profit organization whose mission is to create a bridge between academic research and the pharmaceutical industry, will receive $12 million in funding from the Government of Canada to help academic researchers turn their early discoveries into future medicines.

26 Aug 2014

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with an intense, red, itchy rash on their outer genital organs may be at increased risk of developing urinary tract infections (UTIs), according to new research from Wake Forest Baptist Medical Center. The treatment may be as simple as better hygiene and avoiding potential irritants such as bubble baths and swimming pools.

22 Aug 2014

Blockbuster Fifty Shades linked with greater risk of harmful health behaviors in women

Popular fiction that normalizes and glamorizes violence against women, such as the blockbuster Fifty Shades series, may be associated with a greater risk of potentially harmful health behaviors and risks.

22 Aug 2014

Dr. John S. Sampalis nominated as finalist in the 2014 EY Entrepreneur Of The Year award

Dr. John S. Sampalis is founder and CEO of JSS Medical Research and one of the world's leading clinical epidemiologists. Dr. Sampalis is nominated as a finalist in this year's 2014 EY Entrepreneur Of The Year in the Québec Health Sciences category.

22 Aug 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

22 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Regulation of stem cells in zebrafish embryos results in surprising insights into Alzheimer's Disease

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain.

20 Aug 2014

Research shows long non-coding RNAs regulate circadian clocks

Researchers at UT Southwestern Medical Center have found a new way that internal body clocks are regulated by a type of molecule known as long non-coding RNA.

19 Aug 2014

Cellular Research announces start of early access program for Precise assays

Cellular Research announced today the start of an early access program for its Precise assays and is currently making the product available to 10 sites.

19 Aug 2014

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway.

19 Aug 2014

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A.

18 Aug 2014

HUYA Bioscience International announces strategic partnership with CZCBD

HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).

18 Aug 2014

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended June 30, 2014.

15 Aug 2014

Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

Dyadic International, Inc., a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014.

14 Aug 2014

University of California launches 14 commercial startups in a year

The University of California, Davis, launched 14 commercial startups during the past year to June 30 - the largest number of new ventures based on UC Davis technology to be started in a single year.

14 Aug 2014

Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections such as sepsis could benefit from improved treatment, thanks to a ground-breaking study.

14 Aug 2014

Health institutions tackle high rate of preterm birth

An estimated 15 million babies are born preterm every year and more than one million die within the first 30 days after birth.

14 Aug 2014

Novogen declares shareholder meeting results

Australia-US biotechnology company, Novogen Ltd., an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia.

13 Aug 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Biotechnology News and Research

NEOMED gets $12 million to support academic researchers on drug development

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Blockbuster Fifty Shades linked with greater risk of harmful health behaviors in women

Dr. John S. Sampalis nominated as finalist in the 2014 EY Entrepreneur Of The Year award

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Regulation of stem cells in zebrafish embryos results in surprising insights into Alzheimer's Disease

Research shows long non-coding RNAs regulate circadian clocks

Cellular Research announces start of early access program for Precise assays

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

HUYA Bioscience International announces strategic partnership with CZCBD

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

University of California launches 14 commercial startups in a year

Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Health institutions tackle high rate of preterm birth

Novogen declares shareholder meeting results

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News